Pharmaceutical Contracts with Accession Option
Original notice title
Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
40 / 100
Risk factors
Missing estimated value and award criteria make it difficult to assess tender's attractiveness and fairness.
The notice states it is not a public procurement, which may affect legal recourse and obligations.
No procurement documents available
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2028
- Supply of pharmaceutical products (active substance: Estriol) and combinations as per procurement documents.
- Framework agreement with accession option for additional parties.
Show full summary
This is a framework agreement with an accession option for pharmaceutical products (active substance: Estriol) issued by BARMER Beschaffung und Vergabe in Germany. The procedure is formally labeled as an open procedure, but the notice explicitly states that it is not a public procurement subject to EU directives. The tender covers a single lot and is conducted electronically. The deadline for submission is 1 May 2028. No estimated value or award criteria are provided in the notice.
Risks
Missing estimated value and award criteria make it difficult to assess tender's attractiveness and fairness.
The notice states it is not a public procurement, which may affect legal recourse and obligations.
No procurement documents available
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Administrative
- Electronic submission via Open portal
- Submission deadline: 1 May 2028, 10:00 UTC.
- Language of procedure: German.
Requirements may be incomplete.
Buyer
Location
Wuppertal, DEU
Website
Identifier
992-80322-57
Activity
Health
Lots (1)
LOT-0000
Pharmaceutical Contracts with Accession Option
Framework agreement covering various active substances (details in procurement documents). Includes a one-time extension option of 3 months until 30 September 2028. Place of performance is Wuppertal, Germany.
Location
Duration
Category
Deadline
Award details
Anzahl der Lose: 1 Einzelheiten zu den Wirkstoffen und Wirkstoffkombinationen können den Unterlagen entnommen werden. Die BARMER hat eine einmalige Verlängerungsoption um 3 Monate bis zum 30.09.2028.
Value note
Show original TED data
Original lot title
Arzneimittelverträge mit Beitrittsoption
Original TED description
Anzahl der Lose: 1 Einzelheiten zu den Wirkstoffen und Wirkstoffkombinationen können den Unterlagen entnommen werden. Die BARMER hat eine einmalige Verlängerungsoption um 3 Monate bis zum 30.09.2028.
Procurement Details
- Publication date
- 28 Jun 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 442094-2026
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
40 / 100
Risk factors
Missing estimated value and award criteria make it difficult to assess tender's attractiveness and fairness.
The notice states it is not a public procurement, which may affect legal recourse and obligations.
No procurement documents available
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications